A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment
Status:
Terminated
Trial end date:
2020-09-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of pimodivir after a
single oral dose of 600 milligrams (mg) in adult participants with severe renal impairment
who are not on dialysis and in adult participants with end-stage renal disease (ESRD) who are
not yet on dialysis compared to adult participants with normal renal function (Part A).
Optionally, to evaluate the PK in adult participants with mild and/or moderate renal
impairment compared to adult participants with normal renal function (Part B).